Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
Dinoprostone vaginal insert is a thin, flat, polymeric slab which is rectangular in shape with rounded corners contained within the pouch of an off-white knitted polyester retrieval system. Each slab is buff colored, semitransparent and contains 10 mg of dinoprostone in a hydrogel insert. An integral part of the knitted polyester retrieval system is a long tape designed to aid retrieval at the end of the dosing interval or earlier if clinically indicated. The finished product is a controlled release formulation which has been found to release dinoprostone in vivo at a rate of approximately 0.3 mg/hr.
The chemical name for dinoprostone (commonly known as prostaglandin E2 or PGE2 ) is 11α,15Sdihydroxy- 9-oxo-prosta-5Z,13E-dien-1-oic acid and the structural formula is represented below:
 |
The molecular formula is C20H32O5 and its molecular weight is 352.5. Dinoprostone occurs as a white to off-white crystalline powder. It has a melting point within the range of 65° to 69°C. Dinoprostone is soluble in ethanol and in 25% ethanol in water. Each insert contains 10 mg of dinoprostone in 241 mg of a cross-linked polyethylene oxide/urethane polymer which is a semiopaque, beige colored, flat rectangular slab measuring 29 mm by 9.5 mm and 0.8 mm in thickness. The insert and its retrieval system, made of polyester yarn, are nontoxic and when placed in a moist environment, absorb water, swell, and release dinoprostone.
CERVIDIL is indicated for the initiation and/or continuation of cervical ripening in pregnant women at or near term in whom there is a medical or obstetrical indication for the induction of labor.
Administer one CERVIDIL insert (10 mg) intravaginally for use up to 12 hours (approximately  0.3 mg of dinoprostone is released per hour) [see DOSAGE AND ADMINISTRATION].
Monitor uterine activity, fetal status, and the progression of cervical dilatation and effacement with the use of CERVIDIL. Remove CERVIDIL 12 hours after insertion with the onset of active labor, prior to an amniotomy, occurrence of uterine tachysystole, uterine hypersystole/hypertonicity, or fetal distress [see WARNINGS AND PRECAUTIONS]. Remove CERVIDIL at least 30 minutes prior to administering an oxytocic agent [see WARNINGS AND PRECAUTIONS and DRUG INTERACTIONS].
CERVIDIL should be administered only by trained obstetrical personnel in a hospital setting with appropriate obstetrical care facilities.
Figure 1: Placement of CERVIDIL in the Posterior Vaginal Fornix
 |
Vaginal Insert: 10 mg of dinoprostone (release rate approximately 0.3 mg/hour up to 12 hours) in a hydrogel polymer. The insert is beige-colored, semi-opaque, thin, flat, and rectangular in shape with rounded corners, measuring 29 mm by 9.5 mm by 0.8 mm, contained within an off-white knitted polyester pouch retrieval system (see Figure 2).
Figure 2: CERVIDIL Components
 |
CERVIDIL vaginal insert contains 10 mg dinoprostone in a hydrogel polymer (NDC 0456-412363). The vaginal insert is beige-colored, semi-opaque, thin, flat, and rectangular in shape with rounded corners, measuring 29 mm by 9.5 mm by 0.8 mm, and is contained within an off-white knitted polyester pouch retrieval system.
CERVIDIL is enclosed in an aluminum/polyethylene pack.
Store in a freezer between -20°C and -10°C (-4°F and 14°F). CERVIDIL, enclosed in its aluminum/polyethylene pack, is stable when stored in a freezer for a period of three years. Vaginal inserts exposed to high humidity will absorb moisture from the air and thereby alter the release characteristics of dinoprostone.
Manufactured for: Ferring Pharmaceuticals, Inc. Parsippany, NJ 07054. Revised: Jan 2020
The following adverse reactions are described, or described in greater detail, in other sections:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In placebo-controlled trials of 658 pregnant women (320 CERVIDIL-treated women and 338 placebo-treated women), the following treatment related adverse reactions (see Table 1) occurred at an incidence greater than 2% (and greater than that reported in the placebo group) in the CERVIDIL group [see Clinical Studies].
Table 1: Common Adverse Reactions (≥2%) in Pregnant Patients Near Term Gestation in Trial 11, Trial 21, and Trial 32
| Trials 11 and 21 | ||
| CERVIDIL (N=320) | Placebo (N=338) | |
| Uterine tachysystole with fetal distress | 2.8% | 0.3% |
| Uterine tachysystole without fetal distress | 4.7% | 0% |
| Fetal distress without uterine tachysystole - | 3.8% | 1.2% |
| Trial 32 | ||
| CERVIDIL (N=102) | Placebo (N=104) | |
| Uterine tachysystole with fetal distress | 2.9% | 0% |
| Uterine tachysystole -without fetal distress | 2% | 0% |
| Fetal distress without uterine tachysystole | 2.9% | 1% |
| 1Trial 1 (101-103)and Trial 2 (101-003)evaluated the dinoprostoneinsertonly, without the useofaretrieval system 2Trial 3 (101-801) evaluated the dinoprostoneinsert with the retrieval system. | ||
Drug related fever, nausea, vomiting, diarrhea, and abdominal pain occurred in less than 1% of CERVIDIL-treated patients.
In Trial 3 (with the retrieval system) cases of tachysystole uterine hyperstimulation reversed within 2 to 13 minutes of removal of CERVIDIL. Tocolytics were required in one of the five cases.
The following adverse reactions have been identified during postapproval use of CERVIDIL or other dinoprostone products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Blood and lymphatic system disorders: Disseminated Intravascular Coagulation
Cardiovascular disorders: Myocardial Infarction in women with a history of myocardial infarction
Immune system disorders: Hypersensitivity
Nervous system disorders: Headache
Pregnancy, puerperium and perinatal conditions: Amniotic fluid embolism
Reproductive system: reports of uterine rupture have been reported in association with use of CERVIDIL. Some required a hysterectomy and others resulted in subsequent fetal or neonatal death. Uterine hypertonus
Vascular disorders: Hypotension
CERVIDIL is contraindicated in patients receiving intravenous oxytocic agents because CERVIDIL may augment the activity of oxytocic agents. A dosing interval of at least 30 minutes is recommended for the sequential use of an oxytocic agent following the removal of CERVIDIL.
Included as part of the PRECAUTIONS section.
CERVIDIL should be administered in a hospital setting with an obstetrical care facility.
CERVIDIL should be used with caution in women at high risk of postpartum disseminated intravascular coagulation (DIC). Physiologic or pharmacologic induction of labor, including the use of CERVIDIL, is associated with an increased risk of DIC during the postpartum period. Women aged 30 years or older, those with complications during pregnancy and those with a gestational age over 40 weeks have an increased risk of DIC during the postpartum period. As soon as possible, assess for an evolving fibrinolysis in the immediate post-partum period. Therapy consisting of prompt removal of the source of procoagulant material, replacement of depleted clotting factors and, in some cases, anti-coagulation with heparin should be instituted promptly.
The use of dinoprostone-containing products, including CERVIDIL, can result in inadvertent disruption and subsequent embolization of antigenic tissue causing the development of Amniotic Fluid Embolism Syndrome, a rare and often fatal obstetric condition.
Carefully monitor patients for clinical signs of Amniotic Fluid Embolism Syndrome including hypotension, hypoxemia and respiratory failure, DIC, coma or seizures and provide supportive care as needed.
The use of CERVIDIL may cause uterine tachysystole with or without fetal heart rate changes (see Table 1). While using CERVIDIL, carefully monitor uterine activity, fetal status and the progression of cervical dilatation and effacement. Remove CERVIDIL with any evidence of uterine tachysystole, uterine hypersystole/hypertonicity, fetal distress, or if labor commences. CERVIDIL is contraindicated when prolonged contraction of the uterus is detrimental to fetal safety or uterine integrity, such as previous cesarean section or major uterine surgery, because of the risk of uterine rupture and obstetrical complications (e.g., need for hysterectomy and the occurrence of fetal or neonatal death). Prostaglandins, including CERVIDIL, may potentiate the effect of oxytocin [see DRUG INTERACTIONS]. Remove CERVIDIL at least 30 minutes before administration of an oxytocic agent is initiated and continue to carefully monitor uterine activity. Remove CERVIDIL prior to amniotomy or following rupture of membranes because the higher vaginal pH that occurs with rupture of membranes may result in higher release rate of dinoprostone.
Prostaglandins, including CERVIDIL, can lead to raised intraocular pressure and constriction of pupils. Consider non-prostaglandin cervical ripening procedures in patients with Glaucoma.
Long-term carcinogenicity and fertility studies have not been conducted with dinoprostone. No evidence of mutagenicity has been observed with dinoprostone in the Unscheduled DNA Synthesis Assay, the Micronucleus Test, or the bacteria reverse mutation (Ames) test.
CERVIDIL is indicated for the initiation and/or continuation of cervical ripening in pregnant women at or near term in whom there is a medical or obstetrical indication for the induction of labor. Fetal, neonatal, and maternal risks are discussed throughout the labeling. Limited available data with CERVIDIL use in pregnant women do not show a clear association with adverse developmental outcomes. Relevant animal reproduction data with dinoprostone is not available.
Human Data
In a report of a 3-year pediatric follow-up study, there were no deleterious effects noted on physical examination or psychomotor evaluation of 51 infants born following maternal treatment with CERVIDIL.
Fetal/Neonatal Adverse Reactions
When CERVIDIL was removed for fetal distress, there was a return to normal rhythm and there were no neonatal sequelae. Remove CERVIDIL in the event of persistent tachysystole with or without fetal heart rate changes, and follow established institutional protocols in management of patients.
Concomitant administration of CERVIDIL is not indicated in breastfeeding women. There is no information on the effects of maternal CERVIDIL administration on the breastfed child. Insufficient information is available on the effects of maternal CERVIDIL administration on milk production.
The safety and effectiveness of CERVIDIL have not been established in pregnant girls.
No Information provided
CERVIDIL is contraindicated in patients with:
Dinoprostone is found in low concentrations in most tissues of the body and functions as a local hormone. In pregnancy, dinoprostone is secreted continuously by the fetal membranes and placenta and plays an important role in the final events leading to the initiation of labor including cervical ripening. Dinoprostone stimulates the production of prostaglandin F2α (PGF2α), which sensitizes the myometrium to endogenous or exogenously administered oxytocin. Available evidence indicates that dinoprostone, in the concentrations found during the early part of labor, plays an important role in cervical ripening without affecting uterine contractions.
In most patients, local effects of CERVIDIL on the cervix include changes in the tissue consistency, dilatation and effacement. Some women experience systemic effects, including uterine tachysystole, and uterine hypersystole/hypertonicity, as a result dinoprostone or PGF2α mediated sensitization of the myometrium to oxytocin [see WARNINGS AND PRECAUTIONS].
No specific pharmacodynamic studies were conducted with CERVIDIL.
The delivery rate of dinoprostone from CERVIDIL in vivo is approximately 0.3 mg/per hour over a period of 12 hours. Dinoprostone is metabolized in the tissues of synthesis with the half-life estimated to be 2.5 to 5 minutes. The rate limiting step for inactivation is regulated by the enzyme 15-hydroxyprostaglandin dehydrogenase (PGDH). Any dinoprostone that escapes local inactivation is cleared to the extent of 95% on the first pass through the pulmonary circulation.
No correlation could be established between the release of dinoprostone from CERVIDIL and plasma concentrations of metabolite of dinoprostone (PGEm). The relative contributions of endogenously and exogenously released dinoprostone to the plasma levels of the metabolite PGEm is not known.
The effectiveness and safety of CERVIDIL for the induction of cervical ripening was evaluated in 658 pregnant women (320 CERVIDIL-treated women and 338 placebo-treated women) at or near term in three randomized, double-blind, placebo-controlled trials (Trials 1, 2, and 3). Efficacy outcomes included percentage with treatment success (defined as vaginal delivery within 12 hours, Bishop Score ≥ 6 in the 12-hour observation period, or ≥ 3 increase in the Bishop score in the 12-hour observation period), time to delivery, and time to onset of labor. Table 2 presents efficacy outcomes from Trials 1, 2, and 3.
Table 2: Efficacy Outcomes in Pregnant Women in Trials 11, 2,1 and 32 for CERVIDIL Ripening, Intent-to-Treat Population
| Study # | Primipara/N ullipara | Multipara | P-Value | ||
| CERVIDIL | Placebo | CERVIDIL | Placebo | ||
| Treatment Success* | |||||
| Trial 1 | 65% | 28% | 87% | 29% | <0.001 |
| (N=81) | (n=26) | 2) 3 | (n=16) | (n=7) | |
| Trial 2 | 68% | 24% | 77% | 24% | <0.001 |
| (N=371) | (n=111) | (n=123) | (n=65) | 2) 7 (n=7 | |
| Trial 3 | 72% | 48% | 55% | 41% | 0.003 |
| (N=206) | (n=60) | (n=63) | (n=42) | (n=41) | |
| Median Time to Delivery (hours) | |||||
| Trial 1 | 25.7 | 34.5 | 12.3 | 24.6 | 0.001 |
| (N=81) | (n=26) | (n=32) | (n=16) | (n=7) | |
| Trial 3 | 25.5 | 37.2 | 20.8 | 27.4 | <0.001 |
| (N=206) | (n=60) | (n=63) | (n=42) | (n=41) | |
| Median Time to Onset of Labor (hours) | |||||
| Trial 1 | 12 | 19.2 | 6.9 | 18.3 | <0.001 |
| (N=81) | (n=26) | (n=32) | (n=16) | (n=7) | |
| *Treatment success was defined as vaginal delivery within 12 hours, Bishop score≥6 in the12-hour observation period, or ≥ 3 increase in the Bishop score in the 12-hour observation period. 1Trial 1 and Trial 2 evaluated the dinoprostone insert only, without the use of a retrieval system. 2Trial 3 evaluated the dinoprostone insert with the retrieval system | |||||
Advise the woman to remain in the recumbent position for 2 hours following CERVIDIL insertion and to inform her health care provider immediately if CERVIDIL does not remain in place [see DOSAGE AND ADMINISTRATION].
Inform women that the use of CERVIDIL is associated with an increased risk of disseminated intravascular coagulation (DIC) during the postpartum period [see WARNINGS AND PRECAUTIONS].
Inform women that the use of CERVIDIL can result in inadvertent disruption and subsequent embolization of antigenic tissue causing the development of Amniotic Fluid Embolism Syndrome, a rare and often fatal obstetric condition [see WARNINGS AND PRECAUTIONS].
Inform women that the use of CERVIDIL may cause frequent or prolonged contractions [see WARNINGS AND PRECAUTIONS]. This might result in disruption of blood flow through the placenta and to the fetus.
Inform women that CERVIDIL can lead to raised intraocular pressure and constriction of pupils [see WARNINGS AND PRECAUTIONS].
